遭大股东反对，盟科药业10亿定增“告吹”

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. has announced the termination of its plan to issue shares to specific investors due to significant opposition from its major shareholder, Genie Pharma, which may impact the company's stable operations [1][4]. Group 1: Share Issuance and Opposition - The company initially planned to issue 163,901,373 shares to Nanjing Haiqing Pharmaceutical Co., Ltd. to raise 1.033 billion yuan for daily R&D and operational expenses, which would have resulted in a change of control [2]. - The board approved the share issuance plan, but it did not receive unanimous support, with board member Zhao Yachao voting against it [2][3]. - Zhao Yachao's opposition was based on the lack of thorough investigation into other potential investors, concerns about Haiqing Pharmaceutical's lack of experience in the infection field, and the vague use of raised funds [3]. Group 2: Financial Performance and Challenges - Mengke Pharmaceutical has only one commercialized product, Kantizolam, and has not yet achieved profitability, with revenues of 48.21 million yuan in 2022, 90.78 million yuan in 2023, and projected revenues of 130 million yuan in 2024 [5]. - The company has experienced significant losses, with net profits of -220 million yuan in 2022 and -194 million yuan in the first nine months of 2025 [5]. - The company's debt-to-asset ratio has increased rapidly, reaching 64.57% by the end of September 2025, indicating growing financial pressure [6]. Group 3: Future Considerations - The termination of the share issuance raises questions about how the company will address its production and R&D shortfalls and alleviate financial pressure moving forward [6].